TG Therapeutics, Inc (TGTX) Covered Calls

TG Therapeutics, Inc covered calls TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

You can sell covered calls on TG Therapeutics, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TGTX (prices last updated Thu 3:05 PM ET):

TG Therapeutics, Inc (TGTX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
8.00 -0.03 7.99 8.00 801K - 0.7B
Covered Calls For TG Therapeutics, Inc (TGTX)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
May 17 8 0.55 7.45 7.4% 117%
Jun 21 8 0.90 7.10 12.7% 79.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 is a third generation, type I chimeric IgG1 monoclonal antibody with a glycoengineered Fc region designed specifically to induce higher ADCC activity in comparison to rituximab, which has been demonstrated in pre-clinical models. The TGR-1202, is an orally available PI3K delta inhibitor. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.